

GLYCOMIMETICS INC  
Form 8-K  
July 20, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 15, 2015**

**GlycoMimetics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-36177**  
**(Commission**

**File Number)**  
**9708 Medical Center Drive**

**06-1686563**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: GLYCOMIMETICS INC - Form 8-K

**Rockville, MD 20850**

**(Address of principal executive offices, including zip code)**

**(240) 243-1201**

**(Registrant's telephone number, including area code)**

**401 Professional Drive, Suite 250**

**Gaithersburg, MD 20879**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On July 15, 2015, GlycoMimetics, Inc. (the *Company*) held its 2015 annual meeting of stockholders (the *Annual Meeting*). The stockholders considered two proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on June 15, 2015. Of the 19,017,133 shares outstanding as of the record date, 17,053,758 shares, or 89.7%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

**Proposal No. 1:** Election of two nominees to serve as directors until the 2018 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

<b>Name</b>	<b>Votes For</b>	<b>Votes Withheld</b>
Rachel K. King	12,234,400	476,828
Michael A. Henos	12,209,580	501,648

Broker Non-Votes: 4,342,530.

Both nominees were elected.

**Proposal No. 2:** Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015. The votes were cast as follows:

	<b>Votes For</b>	<b>Votes Against</b>	<b>Abstained</b>
Ratification of appointment of Ernst & Young	17,048,355	5,313	90

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GLYCOMIMETICS, INC.**

Date: July 20, 2015

By: /s/ Brian M. Hahn  
Brian M. Hahn

Chief Financial Officer